文献速递皮肤肿瘤

实体器官移植受者默克尔细胞癌的预后与免疫治疗应答

Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy.
PubMed 文献 · Br J Dermatol · 2025-01-01

该研究基于单中心1988年4月至2024年5月的MCC登记数据,比较37例SOTR与1177例IC患者的基线与结局,并评估8例SOTR接受抗PD-L1的疗效与毒性。SOTR状态与更差预后独立相关,抗PD-L1在部分肾移植受者中有效但可致移植物失功。

要点

  • SOTR的MCC分期更晚,进展、MCC特异性死亡和总死亡风险均显著高于IC患者。
  • 8例肾移植受者接受抗PD-L1,5例客观缓解,但2例在9周内出现不可逆移植物失功。
  • SOTR的MCC预后差,免疫治疗需权衡肿瘤获益与移植物排斥风险。

核心结论

  • SOTR状态是MCC预后更差的显著独立危险因素。
  • 抗PD-L1在部分肾移植受者中显示潜在获益,但可伴随不可逆移植物失功。

研究设计与样本

  • 单中心MCC登记研究,纳入1988年4月至2024年5月共1214例患者(37例SOTR,1177例IC)。
  • 提取人口学、抗PD-L1应答、免疫抑制方案及移植物排斥与失功数据进行分析。

主要发现

  • SOTR中晚期MCC(≥III期)比例为76%,IC患者为51%(P=0.004)。
  • SOTR疾病进展aHR为2.3,MCC特异性死亡aHR为3.0,总死亡aHR为3.9(各自比较P<0.001)。
  • SOTR因MCC死亡的中位时间为2.7年,24%在诊断后1年内死亡,IC患者仅4%。
  • SOTR的MCC进展中位时间为8.6个月,IC患者为12年;SOTR中70%在2年内发生远处转移,IC患者为25%。
  • 8例接受抗PD-L1的SOTR均为肾移植受者,5例(63%)客观缓解(2例完全缓解,3例部分缓解),2例(29%)在9周内出现不可逆移植物失功。

关键数值与推荐

  • SOT至MCC诊断的中位时间为10年(范围0.4–43)。
  • 抗PD-L1在免疫健全晚期MCC患者中约50%产生持久肿瘤应答。

临床怎么用

  • 对SOTR应警惕MCC发生并加强监测,因其分期更晚且预后更差。
  • 对肾移植受者的晚期MCC,抗PD-L1可作为潜在选择,但需密切监测移植物功能与排斥风险。

局限性

  • SOTR样本量小(37例),接受抗PD-L1者仅8例。
  • 为单中心登记回顾性研究。
  • SOTR长期被排除在多数临床试验之外,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive skin cancer with an increased risk of occurrence in immunocompromised patients, including solid organ transplant recipients (SOTRs). As the number of SOTRs rises worldwide, MCC cases in this population are also expected to increase. While anti-programmed cell death 1 ligand 1 (anti-PD-L1; also known as anti-programmed death ligand 1) immunotherapy generates durable tumour responses in ∼50% of immunocompetent (IC) patients with advanced MCC, its efficacy and safety in SOTRs remain uncertain as these patients have been excluded from most clinical trials. OBJECTIVES: To compare baseline characteristics and outcomes among SOTRs and IC patients with MCC, and to evaluate the efficacy and toxicity of anti-PD-L1 in SOTRs. METHODS: We queried an MCC registry from our institution (April 1988-May 2024), extracting data on demographics, anti-PD-L1 response and immunosuppression regimens, along with incidence of allograft rejection and failure, for analysis. RESULTS: We identified 1214 patients with MCC (37 SOTRs and 1177 IC patients); 8 of 37 SOTRs received anti-PD-L1. Median time from SOT to MCC diagnosis was 10 years (range 0.4-43). The proportion of patients with advanced MCC (≥ stage III) was 76% in SOTRs compared with 51% in IC patients (P = 0.004). SOTR status was associated with worse outcomes, including higher rates of disease progression [adjusted hazard ratio (aHR) 2.3], MCC-specific mortality (aHR 3.0) and overall mortality (aHR 3.9) (all P < 0.001 for the respective comparisons). Median time to death due to MCC for SOTRs was 2.7 years; 24% of SOTRs died within one year of diagnosis, in contrast with just 4% of IC patients. Median time to MCC progression for SOTRs was 8.6 months vs. 12 years for IC patients. Among SOTRs, 70% developed distant metastases within 2 years vs. 25% of IC patients. All eight MCC SOTRs treated with anti-PD-L1 were kidney transplant recipients, with five (63%) experiencing an objective response (two complete response, three partial response). However, two patients (29%) experienced irreversible graft failure within 9 weeks. CONCLUSIONS: SOTR status is a significant independent risk factor of a worse prognosis for MCC. This study represents the largest cohort evaluating the efficacy and safety of anti-PD-L1 in SOTRs with advanced MCC, highlighting the potential benefits in this population. Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer. People who have had a solid organ transplant (SOT) are more likely to develop MCC. This is because their immune system is suppressed. Over the past 10 years, the number of people having organ transplants has grown by 43% worldwide. This has come with a rise in SOT MCC cases. But we know little about MCC outcomes for SOT recipients. A first-line treatment for people with advanced MCC is immunotherapy (which boosts the body’s own immune system as a treatment). We lack an understanding of how safe and effective immunotherapy is for SOT recipients, as clinical trials often exclude these individuals. This is because there is a risk of transplanted organ rejection and failure from immunotherapy. In this study, we looked at 1214 patients with MCC (37 SOT recipients, 1177 with unaffected immune systems) in Seattle, USA. We found that SOT recipients were more likely to have advanced MCC (76% vs. 51%). They had greater disease progression and death rates compared with those who had no SOT. We also found SOT recipients were more than twice as likely to experience cancer spread. Eight kidney transplant recipients received immunotherapy. Five of them experienced a decrease in tumour size. Three of those five retained their kidney function. Two of the three remaining patients who had no positive tumour response to immunotherapy retained their kidney function. The third lost kidney function before immunotherapy initiation. In conclusion, we found that although SOT recipients with MCC had poorer outcomes overall, immunotherapy showed promise for some people with kidney transplants. We need more research to improve treatment options for this group.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Akaike T, Ch'en PY, Hippe DS, et al. Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy. Br J Dermatol. 2025. PMID: 40713931. doi:10.1093/bjd/ljaf304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。